Y Intercept (Hong Kong) LTD Tg Therapeutics, Inc. Transaction History

Y Intercept (Hong Kong) LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$13.32 - $19.19 $469,450 - $676,332	35,244 New	35,244 $626,000
Q4 2023 Feb 13, 2024	BUY	$6.68 - $18.81 $32,952 - $92,789	4,933 Added 36.16%	18,577 $317,000
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $3,720 - $11,792	445 Added 3.37%	13,644 $114,000
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $204,320 - $461,965	13,199 New	13,199 $327,000
Q4 2022 Feb 14, 2023	SELL	$5.01 - $11.83 $166,502 - $393,158	-33,234 Closed	0 $0
Q3 2022 Feb 14, 2023	BUY	$4.57 - $8.4 $151,879 - $279,165	33,234 New	33,234 $196,000
Q1 2021 May 12, 2021	SELL	$41.61 - $54.3 $745,151 - $972,404	-17,908 Closed	0 $0
Q4 2020 Feb 05, 2021	BUY	$25.27 - $54.9 $452,535 - $983,149	17,908 New	17,908 $947,000

345

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.86B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.